John Rose

Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

K. P. Johnson, Benjamin Brooks, J. A. Cohen et al. · Neurology · 1995 · 1.9K citations

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability

K. P. Johnson, Benjamin Brooks, J. A. Cohen et al. · Neurology · 1998 · 511 citations

Glatiramer Acetate Treatment, Rheumatology, Clinical Therapeutic +13

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

Daniel Wynn, Michael D. Kaufman, Xavier Montalbán et al. · The Lancet Neurology · 2010 · 298 citations

Disease Progression, Medicine, Immunology +10

Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis

Richard K. Burt, Roumen Balabanov, Joachim Burman et al. · JAMA · 2019 · 287 citations · Full text

Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study

Richard K. Burt, Yvonne Loh, Bruce A. Cohen et al. · The Lancet Neurology · 2009 · 275 citations

Regenerative Medicine, Cell Therapy, Transplantation +11